[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2003302919A1 - Pyridine derivatives as jnk inhibitors and their use - Google Patents

Pyridine derivatives as jnk inhibitors and their use

Info

Publication number
AU2003302919A1
AU2003302919A1 AU2003302919A AU2003302919A AU2003302919A1 AU 2003302919 A1 AU2003302919 A1 AU 2003302919A1 AU 2003302919 A AU2003302919 A AU 2003302919A AU 2003302919 A AU2003302919 A AU 2003302919A AU 2003302919 A1 AU2003302919 A1 AU 2003302919A1
Authority
AU
Australia
Prior art keywords
pyridine derivatives
jnk inhibitors
jnk
inhibitors
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003302919A
Inventor
Elisabeth Kallin
Niklas Plobeck
Britt-Marie Swahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003302919A1 publication Critical patent/AU2003302919A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2003302919A 2002-12-09 2003-12-08 Pyridine derivatives as jnk inhibitors and their use Abandoned AU2003302919A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0203654-9 2002-12-09
SE0203654A SE0203654D0 (en) 2002-12-09 2002-12-09 New compounds
PCT/SE2003/001911 WO2004052880A1 (en) 2002-12-09 2003-12-08 Pyridine derivatives as jnk inhibitors and their use

Publications (1)

Publication Number Publication Date
AU2003302919A1 true AU2003302919A1 (en) 2004-06-30

Family

ID=20289817

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003302919A Abandoned AU2003302919A1 (en) 2002-12-09 2003-12-08 Pyridine derivatives as jnk inhibitors and their use

Country Status (5)

Country Link
AR (1) AR042316A1 (en)
AU (1) AU2003302919A1 (en)
SE (1) SE0203654D0 (en)
TW (1) TW200417546A (en)
WO (1) WO2004052880A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (en) 1999-01-13 2002-10-15 バイエル コーポレイション ω-Carboxyaryl-substituted diphenylureas as p38 kinase inhibitors
DK1478358T3 (en) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
EP1626714B1 (en) 2003-05-20 2007-07-04 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
BRPI0412219B8 (en) 2003-07-23 2021-07-27 Bayer Healthcare Llc fluoro substituted omega-carboxy aryl diphenyl urea compounds and pharmaceutical compositions comprising said compounds
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
CA2651629A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008082487A2 (en) * 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
JP2010514689A (en) * 2006-12-22 2010-05-06 ノバルティス アーゲー Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP2253618A1 (en) * 2008-02-27 2010-11-24 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
CN105237530A (en) 2009-04-03 2016-01-13 豪夫迈罗氏公司 Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
KR20120102669A (en) 2009-11-06 2012-09-18 플렉시콘, 인코퍼레이티드 Compounds and methods for kinase modulation, and indications therefor
KR20130056345A (en) * 2010-09-17 2013-05-29 퍼듀 퍼머 엘피 Pyridine compounds and the uses thereof
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012109075A1 (en) 2011-02-07 2012-08-16 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
WO2012175513A1 (en) 2011-06-20 2012-12-27 Bayer Intellectual Property Gmbh Thienylpyri(mi)dinylpyrazole
IN2014CN02475A (en) 2011-10-06 2015-06-19 Bayer Ip Gmbh
US9023844B2 (en) 2011-10-06 2015-05-05 Bayer Intellectual Property Gmbh Heterocyclylpyri (mi) dinylpyrazole as fungicidals
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2914591B1 (en) * 2012-11-03 2017-10-11 Boehringer Ingelheim International GmbH Inhibitors of cytomegalovirus
JP6588976B2 (en) 2014-10-08 2019-10-09 レッドエックス ファーマ ピーエルシー N-pyridinylacetamide derivatives as Wnt signaling pathway inhibitors
CN107108565B (en) 2014-10-08 2019-08-23 莱德克斯制药公共有限公司 The N- pyridine yl acetamide derivatives of inhibitor as WNT signal transmission approach
BR112021011084A2 (en) * 2018-12-13 2021-08-31 Intervet International B.V. PROCESS FOR PREPARING 1-[(3R,4S)-4-CYANOTETRAHYDROPYRAN-3-IL]-3-[(2-FLUORO-6-METOXY-4-PYRIDYL)AMINO]PYRAZOLE-4-CARBOXAMIDE
CN115417809A (en) * 2022-09-05 2022-12-02 天津药明康德新药开发有限公司 Preparation method of 4, 4-dipyrrole-2, 2-bipyridine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4004012A (en) * 1975-10-14 1977-01-18 Sterling Drug Inc. 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
WO1999032448A1 (en) * 1997-12-19 1999-07-01 Amgen Inc. Substituted pyridine and pyridazine compounds and their pharmaceutical use
DE60135676D1 (en) * 2000-12-05 2008-10-16 Vertex Pharma INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES

Also Published As

Publication number Publication date
TW200417546A (en) 2004-09-16
SE0203654D0 (en) 2002-12-09
WO2004052880A1 (en) 2004-06-24
AR042316A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
AU2003302919A1 (en) Pyridine derivatives as jnk inhibitors and their use
HUS1400047I1 (en) Quinoline derivatives and their use as mycobacterial inhibitors
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
HK1089167A1 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their use 2-
AU2003235676A1 (en) Tricyclic-bis-enone derivatives and methods of use thereof
AU2003298514A1 (en) Methods and compositions using cholinesterase inhibitors
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
AU2003280188A1 (en) Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
PL372756A1 (en) Nicotinamide derivatives useful as pde4 inhibitors
AU2003249669A1 (en) 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
AU2003249909A1 (en) Phenoxypropenylphenyl derivatives and their use as herbicides
AU2003303388A1 (en) Triptolide derivatives and their use
AU2003202116A1 (en) Nicotinamide derivatives useful as pde4 inhibitors
AU2003232848A1 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003289386A1 (en) Jnk inhibitors
AU2003215756A1 (en) Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
AU2003220437A1 (en) Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
AU2003211427A1 (en) Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
AU2003292381A1 (en) Naphthyridine derivatives and their use as fungicides
AU2003297612A1 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003258942A1 (en) Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors
AU2003281691A1 (en) Furoisoquinoline derivative and use thereof
AU2003212515A1 (en) Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
AU2003218715A1 (en) Azepane derivatives and their use as atk1 inhibitors
AU2003900495A0 (en) Aroylhydrazone derivatives and therapeutic uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase